70%Confidence
0Views
FDASource
2026-04-12Date
Summary
Radnostix's Class III recall for a Sodium Iodide I-131 kit component due to specification failures represents a lower-risk issue but still points to manufacturing inconsistencies. This may have limited market impact given the niche nature of the diagnostic product, but it underscores quality challenges in radiopharmaceutical manufacturing.
Actionable: Monitor for any follow-up FDA actions on Radnostix, though the Class III designation suggests minimal immediate business risk.
AI Confidence: 70%
Data Points
firmRadnostix
classificationClass III
statusOngoing
distributionNationwide in the US, including Puerto Rico
productGelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, Internation
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now